<?xml version="1.0"?>
  <rss version="2.0">
    <channel>
      <title>Ezetimibe News : GoldBamboo.com</title>
      <link>http://goldbamboo.com/</link>
      <description>Ezetimibe News from GoldBamboo.com</description>
      <language>en-us</language>
      <copyright>&amp;copy; 2005, Gold Bamboo LLC, All Rights Reserved</copyright>
      
	<item>
        <title>WelChol And Ezetimibe Combination Therapy Provides Significant LDL-C Reductions</title>
        <link>http://goldbamboo.com/news-a206686.html</link>
        <description>A new study found that taking WelChol(R) (colesevelam HCl) in combination with ezetimibe reduced LDL-C by 32%, reducing mean LDL-C levels by an additional 11% over ezetimibe monotherapy in patients with primary hypercholesterolemia (p <; 0.0001). [click link for full article]</description>
		 <pubDate>Tue, 14 Nov 2006 08:00 EST</pubDate>
	</item>
	<item>
        <title>Bad Cholesterol In Patients With Type II Diabetes Studied In Mayo Clinic Proceedings</title>
        <link>http://goldbamboo.com/news-a213263.html</link>
        <description>Results from a clinical study conducted in 1,229 patients with type II diabetes mellitus and high cholesterol showed that VYTORIN® (ezetimibe/simvastatin) provided superior reduction in LDL "bad" cholesterol compared to Lipitor® (atorvastatin) at the dose comparisons studied, according to data published in the December 2006 issue of Mayo Clinic Proceedings. [click link for full article]</description>
		 <pubDate>Thu, 28 Dec 2006 08:00 EST</pubDate>
	</item>
	<item>
        <title>First Study To Evaluate WelChol/Ezetimibe And Simvastatin Effect On LDL-C Finds Additional Lipid Parameter Benefits</title>
        <link>http://goldbamboo.com/news-a206689.html</link>
        <description>Data presented today at the American Heart Association's Scientific Sessions 2006 in Chicago showed that WelChol(R) (colesevelam HCl) plus ezetimibe and simvastatin provides powerful mean LDL-C reductions of 57% from baseline as compared to 51% reductions with ezetimibe plus simvastatin (p less than or equal to 0.0001). [click link for full article]</description>
		 <pubDate>Tue, 14 Nov 2006 08:00 EST</pubDate>
	</item>
	<item>
        <title>FDA Approves New Label For VYTORIN® (ezetimibe/simvastatin)</title>
        <link>http://goldbamboo.com/news-a201627.html</link>
        <description>Merck/Schering-Plough Pharmaceuticals announced today that the U.S. [click link for full article]</description>
		 <pubDate>Fri, 06 Oct 2006 07:00 EST</pubDate>
	</item>
	<item>
        <title>INEGYT Is Superior To Simvastatin In Reducing Key Risk Markers Of Atherosclerosis - Confirmed</title>
        <link>http://goldbamboo.com/news-a197718.html</link>
        <description>Results from new analyses of two clinical studies presented today at the 2006 World Cardiology Congress show that INEGY™ (ezetimibe/simvastatin) is effective for reducing apolipoprotein-B containing lipoproteins (apo-B) and C-reactive protein (CRP), both recognized risk markers for atherosclerosis. [click link for full article]</description>
		 <pubDate>Mon, 11 Sep 2006 11:00 EST</pubDate>
	</item>
	

    </channel>
  </rss>
